Once in a Blue Moon Academia (OBMA)

    Urgent Call to Reassess Piramal Pharma’s Tetmosol Soap A Case for Halting Its Sale Due to Global Questions, Misuse Risks and Ethical Concerns Posted on 1st October, 2025 (GMT 18:11 hrs) ABSTRACT Tetmosol soap, marketed by Piramal Pharma Limited as a treatment for scabies and lice, contains the outdated active ingredient Monosulfiram (5% w/w). While effective for its intended use, Tetmosol’s widespread over-the-counter (OTC) availability in India and other developing regions, coupled with vague marketing claims, has led to rampant misuse for undiagnosed dermatological conditions. This misuse risks ineffective treatment, skin irritation, and delayed diagnoses, raising serious concerns about consumer safety and Mr. Piramal’s ethical responsibility. The article critically examines Tetmosol’s composition, safety, regulatory status, consumer misuse, and Mr. Piramal’s marketing practices, alongside broader enforcement challenges and Mr. Piramal’s product portfolio. It argues...

  Sloan’s “Promise”: Heritage Brand or Hazard in a Bottle? Posted on 1st October, 2025 (GMT 18:38 hrs) ABSTRACT This representation critically examines Sloan’s Liniment/Balm (Piramal Pharma), exposing concerns about its irrational Fixed Dose Combination of counter-irritants (methyl salicylate, menthol, camphor, turpentine oil, eucalyptus oil, capsaicin), absent from global pharmacopeias (USP, Ph. Eur., WHO EML) and unsupported by clinical evidence in arthritis. Risks such as systemic salicylate poisoning, camphor neurotoxicity, turpentine irritation, and capsicum hypersensitivity are compounded by misleading claims of “lasting arthritis relief,” which distract from proper treatment and may delay evidence-based care. Regulatory loopholes in India (Drugs & Cosmetics Act, 1940; Drugs and Magic Remedies Act, 1954) enable this obsolete heritage brand to persist despite international withdrawal. Sloan’s thus embodies an ethical paradox: irritants sold as therapy, financial wound...